Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies

• Published in: Journal of Immunology Research Vol. 2018; no. 2018; pp. 1 - 10
• Main Authors: Zhang, Yi, Yang, Ge, Hao, He, Sun, Shangjun, Fu, Yang
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2018; Hindawi; John Wiley & Sons, Inc; Wiley
• Subjects: Adoptive immunotherapy; Animals; Antigens; Cancer; Cancer therapies; Chemotherapy; Chimeric antigen receptors; Clinical trials; Clinical Trials as Topic; Cytokines; Drug dosages; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Gene therapy; Humans; Immunology; Immunotherapy; Immunotherapy, Adoptive - methods; Leukemia; Lymphocytes; Lymphocytes B; Lymphocytes T; Lymphoma; Lymphoma, B-Cell - immunology; Lymphoma, B-Cell - therapy; Malignancy; Neurotoxicity; Non-Hodgkin's lymphomas; Receptors, Antigen, T-Cell - genetics; Receptors, Antigen, T-Cell - metabolism; Recombinant Fusion Proteins - genetics; Recurrence; Review; Suicide; Suicide genes; T cell receptors; T cells; T-Lymphocytes - immunology; T-Lymphocytes - transplantation; Therapeutic applications; Transcription activation; Trucks; China

T cells modified via chimeric antigen receptors (CARs) have emerged as a promising treatment modality. Unparalleled clinical efficacy recently demonstrated in refractory B-cell malignancy has brought this new form of adoptive immunotherapy to the center stage. Nonetheless, its current success has al...